Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Phase Scientific.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, Asia Molecular Diagnostic Laboratory, Cardinal Health, China Biotech Services Holding, Empiramed, Fitbit, Fujifilm, Fujifilm Irvine Scientific, Happify Health, Life Whisperer, Lifescan, Oncxerna Therapeutics, Pillar Biosciences, Presagen, Pyramid Innovation, Qiagen, Quidel, Statlab Medical Products.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Advaccine, Ascletis, Astrazeneca, Autolus, Bluebird, Biohaven, Calliditas, Dare, Eton, Inovio, Moderna, Relief, Sanofi, Yisheng.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alnylam, Aravive, Axsome, Bavarian Nordic, Biontech, Daiichi Sankyo, Impel, Opthea, Pfizer, Roche, Synedgen, Tracon, Trillium, UCB.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Qiagen, Spintech.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adeor Medical, Amazon Web Services, Avinger, Biomérieux, Caption Health, Clearpoint Neuro, GE Healthcare, SAS, Thermo Fisher Scientific.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akeso, Athersys, Dicerna, Healios, Innovent, Neurocrine.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adhera, Hillevax, J&J, Melior, Neopharm, NRG, Protagonist, Rhythm, Siga, Takeda, Urogen, Zandcell.

Novavax Inc. now says it plans to submit an emergency use authorization (EUA) to the FDA for its highly efficacious COVID-19 vaccine, NVX-CoV2373, sometime in the fourth quarter, backing off previous plans of a second-quarter and then a third-quarter filing.